Philip Gribbon

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)

Translational assays fuel the discovery of new drug modalities

Philip Gribbon, Head of Discovery Research at the Fraunhofern institute of Translational Medicine and Pharmacology, discusses his work on small molecule screening and collaborative drug discovery efforts. Plus, Gribbon explores the use of induced pluripotent stem cells (iPSCs) for translational relevance, highlights a shift towards patient-derived assays, and discusses PROTACs, an exciting new drug modality. These approaches hold promise for enhancing drug discovery and development.



LIKE 0
Philip Gribbon
Clinical Laboratory Diagnostics

Philip Gribbon

Biography

Head of Discovery Research at Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) More
Follow Philip

Philip Gribbon

Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)

Philip Gribbon is the Head of Discovery Research at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) in Hamburg, Germany. He previously served as Assistant Head of Department at Fraunhofer IME - ScreeningPort and was the Chief Scientific Officer at European ScreeningPort. With a background at GlaxoSmithKline and Pfizer, he has contributed significantly to drug discovery and translational medicine throughout his career.